Self-Monitoring of Blood Glucose Study#1: The Ability of People With Diabetes to Use OneTouch(R) Ultrasmart(tm)

This study has been completed.
Sponsor:
Information provided by:
LifeScan
ClinicalTrials.gov Identifier:
NCT00333853
First received: June 2, 2006
Last updated: May 12, 2008
Last verified: May 2008
  Purpose

Insulin therapy requires monitoring and frequent review of glucose levels to optimize dosing. Effective presentation and data analysis are essential. We examined HbA1c changes using the OneTouch(R) UltraSmart(R) System (Test Group), an integrated glucose meter and electronic logbook, compared to established meters with paper logbooks (Control Group).


Condition Intervention
Diabetes
Device: OneTouch(r) UltraSmart(r)

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Official Title: Self-Monitoring of Blood Glucose Study#1: The Ability of People With Diabetes to Use OneTouch(R) Ultrasmart(tm) to Improve Glycemic Control Through Behavioral and Therapeutic Changes

Resource links provided by NLM:


Further study details as provided by LifeScan:

Primary Outcome Measures:
  • Hemoglobin A1c (HbA1c)

Secondary Outcome Measures:
  • Measured hypoglycemia

Estimated Enrollment: 250
Study Start Date: August 2003
Estimated Study Completion Date: June 2005
  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female subjects with type 1 or type 2 insulin-treated diabetes mellitus with a baseline HbA1c greater than or equal to 8.0%.
  • The lower age limit for pediatric subjects was at the discretion of the pediatric investigators and their Institutional Review Board (IRBs).
  • The upper age limit for pediatric subjects was 20 years (i.e., not having reached their 21st birthday on date of enrollment).
  • Subjects must have monitored blood glucose at least 2 times per day. - Subject's current blood glucose meter has download capability, however, the subject did not routinely use this capability on his/her own.

Exclusion Criteria:

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00333853

Locations
United States, California
Diabetes and Endocrine Associates
La Jolla, California, United States, 92037
Children's Hospital, Los Angeles
Los Angeles, California, United States, 90027
United States, Florida
University of Miami Miller School of Medicine
Miami, Florida, United States, 33136
United States, Maryland
University of Maryland School of Medicine
Baltimore, Maryland, United States, 21201
United States, Massachusetts
Joslin Diabetes Center
Boston, Massachusetts, United States, 02215
United States, Missouri
Washington University School of Medicine
St. Louis, Missouri, United States, 63110
United States, Oregon
Radiant Research
Portland, Oregon, United States, 97239
Sponsors and Collaborators
LifeScan
Investigators
Principal Investigator: Lori Laffel, MD, MPH Joslin Diabetes Center
  More Information

Publications:
Responsible Party: LifeScan, Inc.
ClinicalTrials.gov Identifier: NCT00333853     History of Changes
Other Study ID Numbers: DDI 70-97017-17
Study First Received: June 2, 2006
Last Updated: May 12, 2008
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Diabetes Mellitus
Endocrine System Diseases
Glucose Metabolism Disorders
Metabolic Diseases

ClinicalTrials.gov processed this record on October 29, 2014